Morbidities and comorbidities associated with optic nerve hypoplasia and septo-optic-pituitary dysplasia
- PMID: 39804979
- DOI: 10.1111/dmcn.16235
Morbidities and comorbidities associated with optic nerve hypoplasia and septo-optic-pituitary dysplasia
Abstract
Aim: To quantify optic nerve hypoplasia (ONH) and septo-optic-pituitary dysplasia (SOD) morbidities and comorbidities.
Method: A retrospective population-based study with a case-control design was undertaken using administrative health data from Manitoba, Canada. Cases were 124 patients with ONH or SOD (70 males, 54 females; age range 6 months-36 years 8 months [mean 13 years, SD 7 years 2 months]) diagnosed from 1990 to 2019, matched to 620 unrelated population-based controls (350 males, 270 females; age range 0-36 years 8 months [mean 12 years 5 months, SD 7 years 2 months]) on birth year, sex, and area of residence. Additionally, 76 cases with ONH or SOD (46 males, 30 females; age range 2 years 5 months-36 years 8 months [mean 13 years 11 months, SD 7 years 3 months]) were matched one-to-one with sibling controls (40 males, 36 females; age range 7 months-33 years 1 month [mean 11 years 8 months, SD 7 years 3 months]). We used χ2 or Fisher's exact tests to test for differences in prevalence in morbidities and comorbidities between cases and controls; odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. Cox proportional hazards models were used to test for differences in subgroups of cases; hazard ratios and 95% CIs were estimated.
Results: Visual impairment and visual impairment with hypopituitarism were core morbidities associated with ONH and SOD cases respectively compared to unrelated controls (OR = 58.6, 95% CI = 22.5-152.5; OR = 243.4, 95% CI = 32.9-1799.0 respectively). Developmental delay or intellectual disability (OR = 6.9, 95% CI = 3.3-14.4), autism spectrum disorder (OR = 4.0, 95% CI = 2.0-8.3), epilepsy (OR = 14.9, 95% CI = 6.1-36.5), cerebral palsy (OR = 40.9, 95% CI = 14.0-119.6), and mood or anxiety disorders (OR = 1.7, 95% CI = 1.0-2.8) were the comorbidities more common among cases with ONH and SOD. Cases matched to siblings showed similar results except for mood and anxiety disorders.
Interpretation: Visual impairment and visual impairment with hypopituitarism are the main morbidities in patients with ONH and SOD respectively, while developmental delay or intellectual disability, autism spectrum disorder, epilepsy, cerebral palsy, and mood or anxiety disorders are important comorbidities.
© 2025 Mac Keith Press.
Similar articles
-
Risk factors in children with optic nerve hypoplasia and septo-optic dysplasia.Dev Med Child Neurol. 2024 Jan;66(1):106-116. doi: 10.1111/dmcn.15678. Epub 2023 Jul 2. Dev Med Child Neurol. 2024. PMID: 37394738
-
Neurodevelopmental impairments in children with septo-optic dysplasia spectrum conditions: a systematic review.Mol Autism. 2023 Jul 25;14(1):26. doi: 10.1186/s13229-023-00559-0. Mol Autism. 2023. PMID: 37491272 Free PMC article.
-
Neuroimaging Features in Children with Optic Nerve Hypoplasia and Septo-Optic-Pituitary Dysplasia.Can J Neurol Sci. 2024 May;51(3):416-424. doi: 10.1017/cjn.2023.263. Epub 2023 Jul 26. Can J Neurol Sci. 2024. PMID: 37492885
-
Epileptic Spasms in Septo-Optic-Pituitary Dysplasia: A Retrospective Cohort Study.Pediatr Neurol. 2025 Sep;170:98-105. doi: 10.1016/j.pediatrneurol.2025.06.019. Epub 2025 Jun 26. Pediatr Neurol. 2025. PMID: 40664004
-
Psychological therapies for the treatment of mental disorders in low- and middle-income countries affected by humanitarian crises.Cochrane Database Syst Rev. 2018 Jul 5;7(7):CD011849. doi: 10.1002/14651858.CD011849.pub2. Cochrane Database Syst Rev. 2018. PMID: 29975811 Free PMC article.
Cited by
-
Septo-optic Dysplasia in a Patient With Increased Socioeconomic Needs: A Case Report.Cureus. 2025 Feb 4;17(2):e78479. doi: 10.7759/cureus.78479. eCollection 2025 Feb. Cureus. 2025. PMID: 40062035 Free PMC article.
-
Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.Obes Pillars. 2025 Jul 1;16:100192. doi: 10.1016/j.obpill.2025.100192. eCollection 2025 Dec. Obes Pillars. 2025. PMID: 40698016 Free PMC article.
References
REFERENCES
-
- Garcia‐Filion P, Borchert M. Optic nerve hypoplasia syndrome: a review of the epidemiology and clinical associations. Curr Treat Options Neurol 2013; 15(1): 78–89.
-
- Salman MS, Hossain S, Rozovsky K. Neuroimaging features in children with optic nerve hypoplasia and septo‐optic‐pituitary dysplasia. Can J Neurol Sci 2024; 51(3): 416–24.
-
- Khaper T, Bunge M, Clark I, Rafay MF, Mhanni A, Kirouac N, et al. Increasing incidence of optic nerve hypoplasia/septo‐optic dysplasia spectrum: Geographic clustering in Northern Canada. Paediatr Child Health 2017; 22(8): 445–53.
-
- Mohney BG, Young RC, Diehl N. Incidence and associated endocrine and neurologic abnormalities of optic nerve hypoplasia. JAMA Ophthalmol 2013; 131(7): 898–902.
-
- Margalith D, Jan JE, McCormick AQ, Tze WJ, Lapointe J. Clinical spectrum of congenital optic nerve hypoplasia: review of 51 patients. Dev Med Child Neurol 1984; 26(3): 311–22.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical